Stroke and Traumatic Acute Brain Injury Line Indicator System for Emergent Recognition (STABILISER-I)

Traumatic Brain Injury Clinical Trial

— STABILISER-I  

Official title:

Stroke and Traumatic Acute Brain Injury Line Indicator System for Emergent Recognition (STABILISER-I)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02514902
• Other study ID #: 15-0166-F6A
• Secondary ID: NIH UL1TR000117
• Status: Completed
• Phase: N/A
• First received: July 29, 2015
• Last updated: February 20, 2017
• Start date: March 25, 2015
• Est. completion date: December 16, 2016

Study information

• Verified date: February 2017
• Source: University of Kentucky
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In the search for a novel marker of stroke that could be rapidly assessed in blood, the investigators developed a point-of-care (POC) lateral flow device (LFD) that rapidly (< 15 min) detects levels of a biomarker that is released into blood following neuronal injury associated with stroke and traumatic brain injury. The protein's expression in human brain should serve as a useful biomarker of neuronal injury in stroke and traumatic brain injury.

Description:

The use of a lateral flow device (LFD) to indicate the presence of a blood biomarker is feasible and may provide an important diagnostic tool for stroke and traumatic brain injury (TBI).

Primary Objectives:

1. Determine the first-in-humans feasibility using the investigators' biomarker lateral flow device on whole blood samples to diagnose patients with acute stroke (both ischemic and hemorrhagic) and traumatic brain injury being evaluated in the Emergency Department and Inpatient Services at University of Kentucky. Provide initial pilot data for estimating sensitivity and specificity of the assay.

2. Establish a visual ordinal grading scale that is easy to use clinically to judge the severity of injury, from the Lateral Flow Device result. Verify that the visual scale has inter-rater reliability, and evaluate it against a digital detection assay.

3. Examine the correlation between clinical and radiographic parameters of injury severity and blood levels of the biomarker. The investigators will correlate the results of the test with NIH Stroke Scale and with MRI infarct volume for ischemic stroke, with hemorrhage volume on CT for hemorrhagic stroke, and with Glasgow Coma Scale for Traumatic Brain Injury (TBI).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: December 16, 2016
• Est. primary completion date: December 16, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Patients 21-85 years old, male or female.

2. Suspected TBI, acute ischemic stroke, or nontraumatic/nonlesional intracerebral hemorrhage (ICH) based on clinical and radiographic evidence as determined and documented by the appropriate service (Trauma Service or Neurosurgery Service for TBI; Neurology or Neurosurgery Service for Stroke) at University of Kentucky.

3. Patients with impaired capacity may be included; as the pathology to be studied (stroke or TBI) may impair their capacity (please see attached required documentation regarding impaired capacity).

Exclusion Criteria:

1. Pregnant women as the effect of pregnancy on the biomarker testing result is as yet unknown.

2. While patients may be included with the above listed diagnoses, they may be excluded later if an alternate unlisted diagnosis is found to be the root cause of their presentation. An example would be a patient initially thought to have a stroke, who is discovered to be suffering from a seizure instead.

Related Conditions & MeSH terms

• Brain Injuries
• Hemorrhagic Stroke
• Ischemic Stroke
• Stroke
• Traumatic Brain Injury
• Wounds and Injuries

Intervention

Device:
• Lateral Flow Device
A drop of whole blood from a finger stick is placed on the lateral flow device at two different time points to indicate the presence of a neuronal specific biomarker. The results will also be correlated to severity of clinical and radiographic injury. Separate drops are evaluated similarly for serum levels. The objective is to determine feasibility of a diagnostic tool for stroke (ischemic and hemorrhagic and traumatic brain injury (TBI). No diagnostic results or resulting treatments will be applied to any subject.

Locations

Country	Name	City	State
United States	University of Kentucky Deparment of Neurosurgery, UK Chandler Hospital	Lexington	Kentucky

Sponsors (2)

Lead Sponsor	Collaborator
Justin Fraser	University of Kentucky

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Whole Blood Biomarker Results on the Visual Analog Scale	Degree of response to a protein specific biomarker in whole blood as indicated by the Lateral Flow Device's analog scale: negative / mild / moderate / severe.	Within 8 hours of time of injury/onset of stroke symptoms.
Secondary	Whole Blood Biomarker Results on the Visual Analog Scale	Degree of response to a protein specific biomarker in whole blood as indicated by the Lateral Flow Device's analog scale: negative / mild / moderate / severe.	Within 48 ± 8 hours of time of injury/onset of stroke symptoms.
Secondary	Serum Biomarker Results on the Visual Analog Scale	Degree of response to a protein specific biomarker in serum as indicated by the Lateral Flow Device's analog scale: negative / mild / moderate / severe.	Within 8 hours of time of injury/onset of stroke symptoms.
Secondary	Serum Biomarker Results on the Visual Analog Scale	Degree of response to a protein specific biomarker in serum as indicated by the Lateral Flow Device's analog scale: negative / mild / moderate / severe.	Within 48 ± 8 hours of time of injury/onset of stroke symptoms.